PerkinElmer logo
App Note

Assessment of drug efficacy and toxicity by combining innovative technologies

Download App Note

Document preview

  • mockup--Reagents_Alpha-HTRF-ATPLite_drug-efficacy-toxicity-detection_AppNote_Page_1
  • mockup--Reagents_Alpha-HTRF-ATPLite_drug-efficacy-toxicity-detection_AppNote_Page_2
  • mockup--Reagents_Alpha-HTRF-ATPLite_drug-efficacy-toxicity-detection_AppNote_Page_4

Compound MoA and potential cytotoxic effects deciphered thanks to immunoassays and cell viability assay

The attrition of drug molecules occurs at various stages in the development process, and most early-phase failures are attributed to safety and toxicity issues. Considering the economic impact of early project termination, the biggest challenge comes from selecting the most potent and selective drug compounds while assessing their potential toxic side effects.

In this application note, you’ll discover how to easily combine AlphaLISA®, HTRF®, or AlphaLISA® SureFire® Ultra™ immunoassays with the ATPlite™ 1step cell viability assay to simultaneously, and in a single sample, study the efficacy of drug compounds on disease pathways while identifying possible cytotoxic effects.

  1. Recommendations

  2. Detailed workflows

  3. Case studies on various cell lines and different markers using HTRF, AlphaLISA, or AlphaLISA SureFire Ultra immunoassays together with the ATPlite 1step cell viability assay

Download App Note